

REVIEWER'S REPORT

Manuscript No.: IJAR-54616

Date: 3/11/2025

Title: PHARMACOLOGIC THERAPY OF POSTMENOPAUSAL OSTEOPOROSIS: AN UPDATED NARRATIVE REVIEW OF GUIDELINES AND EVIDENCE

Recommendation:

- ✓ Accept as it is
- Accept after minor revision.....
- Accept after major revision
- Do not accept (*Reasons below*)

Rating	Excel.	Good	Fair	Poor
Originality		✓		
Techn. Quality		✓		
Clarity		✓		
Significance	✓			

Reviewer Name: Dr. S. K. Nath

Date: 4/11/2025

Reviewer's Comment for Publication:

Overall, this is a well-structured, evidence-based review that offers valuable guidance for clinicians managing postmenopausal osteoporosis. Its comprehensive coverage and emphasis on individualized therapy are commendable. To enhance its impact, integrating critical appraisal of evidence, expanding on safety management, and improving clarity would be beneficial.

Reviewer's Comment / Report

Strengths:

- Comprehensive Scope:** The paper thoroughly covers a broad range of pharmacological options, including bisphosphonates, denosumab, anabolic agents, SERMs, hormone therapy, and calcitonin. It synthesizes guidelines and evidence from recent landmark trials effectively.
- Updated Guidelines and Evidence:** The review reflects the latest clinical guidelines and integrates data from randomized controlled trials, extension studies, and meta-analyses, making it highly relevant for clinicians.
- Focus on Personalized Treatment:** Emphasizing risk stratification, therapy sequencing, and goal-directed therapy aligns with modern personalized medicine approaches, which enhances its clinical applicability.
- Use of Visual Aids:** Inclusion of figures such as the treatment algorithm and site-specific therapy stratification (Figures 1 and 4) improves clarity and practical understanding.

Weaknesses:

- Lack of Critical Appraisal:** While the review summarizes current evidence, it does not deeply critically evaluate the limitations of the cited studies, such as potential biases, study populations, or differences in trial designs.
- Limited Discussion on Long-Term Safety:** Although adverse effects like atypical femoral fractures and osteonecrosis are mentioned, the discussion could be expanded to include recent updates on management and mitigation strategies for these safety concerns.
- Language and Clarity:** Several sentences are lengthy and could benefit from clearer, more concise phrasing to enhance readability. Some technical jargon might be challenging for non-specialist readers.
- Absence of Patient-Centered Outcomes:** Few mentions of patient-reported outcomes, quality of life, or adherence strategies, which are critical in real-world management.
- Formatting and Typographical Checks:** Some references and figure citations lack uniform formatting, and minor typographical errors could be present (e.g., inconsistent spacing or punctuation), although these are not explicitly detailed in the excerpts.

International Journal of Advanced Research

Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

REVIEWER'S REPORT

Author Instructions:

1. **Proofreading:** Carefully review the manuscript for typographical and grammatical errors. Standardize reference and figure citations throughout.
2. **Clarity:** Break down lengthy sentences and simplify complex jargon where possible for broader comprehension.
3. **Expand Safety Discussion:** Include recent updates on the management of adverse effects such as AFF and ONJ, with practical recommendations.
4. **Add Patient Perspectives:** Consider adding a section or paragraph on adherence strategies, patient-reported outcomes, and quality of life.
5. **Critical Analysis:** Incorporate a brief discussion on limitations of current evidence and future research directions.